

1645

Atty. Docket No.: 10939/2022

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mochizuki, et al.
Serial No.: 09/834,008
Filed: April 12, 2001
Entitled: BONE-PATHOBOLISM
TREATING AGENT

Examiner:

Group Art Unit 1645

Conf. No.: 4949


RECEIVED
JUN 11 2001
TECH CENTER 1600/290

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Nancy Arsenault

Name of Person Mailing Paper


Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER


Enclosed for filing in the above-identified patent application, please find the following documents:


1. Information Disclosure Statement;
2. Form PTO-1449
3. Copies of Cited References;
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 10939/2022.
A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date:


June 5, 2001



Name: Paula Campbell Evans

Registration No.: 32,503

Palmer & Dodge LLP

One Beacon Street

Boston, MA 02108

Tel: 617-573-0100



Atty. Docket No.: 10939/2022

PATENT

TECH CENTER 1600/2200

JUN 11 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mochizuki, et al.
Serial No.: 09/834,008
Filed: April 12, 2001
Entitled: BONE-PATHOBOLISM
TREATING AGENT

Examiner:

Group Art Unit: 1645

Conf. No.: 4949

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.


Respectfully submitted,

Date:

June 5, 2001

Paula Campbell Evans

Name: Paula Campbell Evans
Registration No.: 32,503
Palmer & Dodge LLP
One Beacon Street
Boston, MA 02108
Tel: 617-573-0100

USPTO Form 122 Patent and Trademark Office		Department of Commerce		Attorney Docket No. 10939/2022		Serial No. 09/834,008	
INFORMATION DISCLOSURE STATEMENT				Applicant(s): Mochizuki, et al.			
				Filing Date: April 12, 2001		Group: 1653 1645	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation
							YES NO
CMK	A.	EP 0 816 380 A1	07/01/98	European	C07K	14/52	x
CMK	B.	WO 98/46211	22 October 1998	PCT	A61K	9/16	x
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
CMK	C.	Tomoyasu, et al., Characterization of Monomeric and Homodimeric Forms of Osteoclastogenesis Inhibitory Factor, Biochemical and Biophysical Research Communications 23, 382-387 (1998).					
	D.	Yamamoto, et al., Hypocalcemic Effect of Osteoclastogenesis Inhibitory Factor/Osteoprotegerin in the Thyroparathyroidectomized Rat, Endocrinology Vol, 139, No. 9 (1998), pp 4012-4015.					
	E.	Chowdhury, et al., Effects of Heparin on Osteoclast Activity, Journal of Bone and Mineral Research, Vol. 7, Number 7, (1992), pp 771-777.					
	F.	Cochran and Abernathy, Modulation of Bone Resorption by Glycosaminoglycans: Effects of Parathyroid Hormone and Interleukin-1, Bone, 9, 331-335 (1988).					
	G.	Nobuyuki, et al., Remedy for Osteopathy, Publication No. 62-201825 (1987). abstract only					
CMK	H.	Chemical Abstracts Vol. 123, Page 662, (1995).					
EXAMINER					DATE CONSIDERED		
					2/4/03		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							